U.S. markets open in 6 hours 7 minutes

Standard BioTools Inc. (LAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7000-0.0300 (-1.10%)
At close: 04:00PM EDT
2.7000 0.00 (0.00%)
After hours: 04:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.7300
Bid0.0000 x 1400
Ask0.0000 x 900
Day's Range2.6495 - 2.7282
52 Week Range0.9200 - 3.1600
Avg. Volume257,081
Market Cap225.655M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-1.0100
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LAB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Standard BioTools Inc.
    Analyst Report: Becton, Dickinson And Co.Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.
    Fair Value
    Economic Moat
    15 hours agoArgus Research
View more
  • Thomson Reuters StreetEvents

    Q2 2023 Standard BioTools Inc Earnings Call

    Q2 2023 Standard BioTools Inc Earnings Call

  • GlobeNewswire

    Standard BioTools Reports Second Quarter 2023 Financial Results

    Continued operational execution improves revenue growth, margin expansion, and expense reductionSOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) (“Standard BioTools”, or the “Company”), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the second quarter ended June 30, 2023. Selected Financial Results (Numbers in millions, except percentages)Quarter EndedJune 30, 2023 Qu

  • GlobeNewswire

    Standard BioTools to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences: Canaccord Genuity 43rd Annual Growth Conference: Michael Egholm, PhD, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, August 9, 2023, at 3:30 p.m. ET.UBS MedTech, Tools and Geno